What is Bionova Scientific?
Bionova Scientific is a prominent biologics CDMO focused on the development and manufacturing of monoclonal antibodies (mAbs) and therapeutic proteins. Leveraging advanced mammalian cell culture processes, the company provides a comprehensive suite of services, including research and development, protein production, and analytical sciences. Bionova is committed to a client-centric approach, delivering flexible and rapid solutions tailored to the unique needs of biopharmaceutical clients, thereby empowering innovation in protein-based therapeutics.
How much funding has Bionova Scientific raised?
Bionova Scientific has raised a total of $22M across 1 funding round:
Other Financing Round
$22M
Other Financing Round (2019): $22M with participation from Great Point Partners
Key Investors in Bionova Scientific
Great Point Partners
Great Point Partners is a leading health care investment firm with a strong track record of providing growth equity and financing to over 100 companies across the biopharmaceutical services, pharmaceutical infrastructure, and healthcare IT sectors. Their investment in Bionova Scientific highlights a strategic focus on companies advancing biopharmaceutical development and manufacturing.
What's next for Bionova Scientific?
With the recent infusion of major strategic capital, Bionova Scientific is poised for significant expansion. This investment will likely fuel advancements in their manufacturing capacity and technological capabilities, enabling them to handle an increased volume of complex biologics projects. The company's focus on problem-solving and client success, combined with its expertise in mammalian cell culture, positions it for continued leadership and growth within the competitive biopharmaceutical services market. Future developments may include enhanced service offerings and strategic partnerships to further solidify its market position.
See full Bionova Scientific company page
